Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

House dust mite allergy immunotherapy tablet - Stallergenes Greer plc

Next Previous
Drug Profile

House dust mite allergy immunotherapy tablet - Stallergenes Greer plc

Alternative Names: Actair; House dust mite allergy immunotherapy - Stallergenes Greer plc; House dust mite SLIT; House dust mite sublingual immunotherapy; Oralair Mites; S-524101; STAGR 320; STG 320

Latest Information Update: 10 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stallergenes SA
  • Developer Shionogi; Stallergenes Greer plc
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic asthma; Perennial allergic rhinitis

Most Recent Events

  • 20 Nov 2018 Stallergenes announces intention to submit BLA to the US FDA as well as for additional marketing authorizations in European and international markets for Perennial allergic rhinitis
  • 20 Nov 2018 Efficacy data from a phase III trial in Perennial allergic rhinitis released by Stallergenes Greer
  • 21 Jun 2018 Stallergenes Greer completes a phase III trial for Perennial allergic rhinitis (In adolescents, In adults) in USA, France, Germany, Belgium, Slovakia, Czech Republic, Bulgaria, Poland and Spain (PO, Sublingual) (NCT02443805) (EudraCT2014-004223-46)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top